Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
U69 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia/Lymphoma
NCT07350863Phase 1Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Oct 2026
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of U69 in t-cell acute lymphoblastic leukemia (T-ALL) and T cell lymphoblastic lymphoma (T-LBL) (3 arms), sponsored by First Affiliated Hospital of Soochow University. Primary endpoints: Dose-limiting toxicity at 28 days, Adverse Event at 2 years and 1 more. Started Oct 2026; status: recruiting.
02
Drugs
U69
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)T cell lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on NCT07350863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07350863.